drugset / Trial / NCT01238588

The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan

NCT01238588

Terminated 24 enrolled Brigham and Women's Hospital
NaSingle-groupOpen-labelTreatment

Summary

The hypothesis is that switching calcium based phosphate binders to sevelamer carbonate will be associated with less inflammation including less atherosclerotic plaque inflammation (inflammation of the vessel walls).

Timeline

Start
2011-06-10
Primary completion
2016-04-08
Completion
2016-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Sevelamer Other / unclassified